Professional Profile
Mr. Philip Cyr is Senior Vice President of the Pharmaceutical Commercialization Practice for HEORStrategies, a Division of ToxStrategies LLC. Mr. Cyr has over 30 years of experience developing and commercializing therapies. This experience encompasses research and development, clinical trials, health economics and outcomes research (HEOR), health policy and health technology assessments, pricing and market access, and medical affairs.
Mr. Cyr possesses a comprehensive understanding of global HEOR, market access, and commercialization environments, with deep and broad therapeutic knowledge that includes neurology and psychiatry, cardiology, infectious disease, metabolic disorders, gastrointestinal issues, oncology, immunology, and rare diseases. In addition, Mr. Cyr specializes in cell and gene therapy. Mr. Cyr has been involved in building the health economic evidence and value demonstration strategies for over 25 cell and gene therapies, and was instrumental in launching the therapies ZOLGENSMA, LUXTURNA, LENMELDY, and YESCARTA.
In addition to his consulting work, Mr. Cyr serves as a guest lecturer in cell and gene therapy at Georgetown University. He has previously been research faculty at University of North Carolina at Charlotte College of Health and Human Services, and an adjunct professor at George Mason University School of Management.